MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.41
+0.06
+0.94%
Closed 16:41 05/05 EDT
OPEN
6.35
PREV CLOSE
6.35
HIGH
6.65
LOW
6.30
VOLUME
207.66K
TURNOVER
--
52 WEEK HIGH
11.52
52 WEEK LOW
6.06
MARKET CAP
299.14M
P/E (TTM)
-4.4669
1D
5D
1M
3M
1Y
5Y
Proton Pump Inhibitors Market Emerging Technologies, Growing Opportunity and Adoption of Innovative Trends Offerings to New Investment Opportunities
Market Insight Reports · 04/16 10:09
Global IBS Treatment Market Trend Analysis 2021, Product Scope, Business Growth, Top Leading Key Players with Industry Perspectives, Share, Revenues, Impact of Covid-19 and Forecast to 2027
Apr 15, 2021 (The Expresswire) -- Final Report will add the analysis of the impact of COVID-19 on this industry. Global “IBS Treatment Market” research...
The Express Wire · 04/15 08:54
TENX: HELP Results & New Asset to Boot
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT
Benzinga · 04/14 15:51
Choroidal Neovascularization Drug market 2021 : Growth Analysis By Top Countries Data, Market Size, Share, News, Demand, Segments and Forecast to 2027
Apr 12, 2021 (Market Insight Reports) -- The latest report as Choroidal Neovascularization Drug Market acknowledges Size, Application Segment, Type, Regional...
Market Insight Reports · 04/12 09:42
DSMB gives green light for RedHill Bio's late-stage opaganib study in COVID-19
The independent Data Safety Monitoring Board ((DSMB)) has unanimously recommended to continue the study of RedHill Biopharma's (RDHL) Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640) in patients hospitalized with
Seekingalpha · 04/09 11:42
BRIEF-Redhill Biopharma's Phase 2/3 Covid-19 Study Of Opaganib Passes Fourth DSMB Review With Unanimous Recommendation To Continue
reuters.com · 04/09 11:07
MARA, BLUE, TME and CAN among premarket gainers
Universe Pharmaceuticals (UPC) +113%.Humanigen (HGEN) +61% on positive Phase 3 data for COVID-19 therapy.Cyanotech Corporation (CYAN) +48%.Big Rock Partners Acquisition (BRPA) +42%.SeaChange International (SEAC) +34% on multi-million-dollar contract with b...
Seekingalpha · 03/29 12:20
5 Israeli Stocks To Consider For Passover
Back in the days of the Exodus, investment opportunities in the Holy Land were limited to a pair of options. One choice was framed by draconian terms of service that were literally chiseled in stone and regulated by an often-severe oversight authority, alt...
Benzinga · 03/27 12:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDHL. Analyze the recent business situations of Redhill Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDHL stock price target is 20.60 with a high estimate of 26.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 79
Institutional Holdings: 11.98M
% Owned: 25.67%
Shares Outstanding: 46.67M
TypeInstitutionsShares
Increased
23
296.73K
New
15
480.73K
Decreased
13
248.88K
Sold Out
7
101.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/Chief Executive Officer/Director
Dror Ben-Asher
Chief Financial Officer
Micha Ben Chorin
Finance Director
Einav Nagar-Brenner
Chief Operating Officer
Gilead Raday
Senior Vice President/Director of Sales/Director of Marketing
Rob Jackson
Senior Vice President
Patricia Anderson
Senior Vice President
Reza Fathi
Senior Vice President
Robert Gilkin
Senior Vice President
David Wasserman
Chief Scientific Officer
June Almenoff
Vice President - Finance
Todd Krzyzaniak
Vice President/Director of Human Resources
Michelle Snelling
Vice President
Danielle Abramson
Vice President
Aida Bibliowicz
Vice President
Ben Martie
Vice President
Shani Maurice
Vice President
Craig Miller
Vice President
Steven Thomasian
Vice President
Reginald Williams
Other/Director
Rick Scruggs
Other
Adi Frish
Other
Guy Goldberg
Director
Alessandro Della Cha
Independent Director
Shmuel Cabilly
Independent Director
Alla Felder
Independent Director
Kenneth Reed
Independent Director
Eric Swenden
Independent Director
Ofer Tsimchi
No Data
  • All
  • Financials
  • Insiders
More
About RDHL
Redhill Biopharma Ltd is an Israel-basedis a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The Company promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.

Webull offers kinds of RedHill Biopharma Ltd (ADR) stock information, including NASDAQ:RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.